

## Hydrix (ASX:HYD) implants first female patient in Singapore with AngelMed Guardian

ASX:HYD MCAP \$41.70M

Ashleigh Melanko 22 October 2020



- Hydrix (HYD) has implanted its first female patient in Singapore with its AngelMed Guardian device
- This marks the fifth patient to successfully receive the implant in the country
- The AngelMed Guardian uses machine learning algorithms and artificial intelligence to continuously monitor the patient's heart signal
- This then warns medical professionals of any coronary symptoms such, as silent heart attacks
- Hydrix has ended the day 3.03 per cent in the green with shares trading for 34 cents each

Hydrix (HYD) has implanted its first female patient in Singapore with its AngelMed Guardian device.

The patient who received the implant has been discharged from hospital and is in good health.

This marks the [fifth patient](#) to successfully receive the AngelMed Guardian implant in Singapore.

Further, the implant was performed under the supervision of Cardiologist Dr Leslie Lam.

"With each procedure, awareness of the AngelMed Guardian technology grows. We look forward to more procedures being announced in the near future," General Manager Paul Kelly said.

The AngelMed Guardian uses machine learning algorithms and artificial intelligence to continuously monitor the patient's heart signal and warn of any coronary syndrome, such as silent heart attacks.

Hydrix has ended the day 3.03 per cent in the green with shares trading for 34 cents each in a \$41.70 million market cap.

<https://themarket Herald.com.au/hydrix-asxhyd-implants-first-female-patient-in-singapore-with-angelmed-guardian-2020-10-22/>